Skip to main content

Table 2 Effect of krill powder supplementation on plasma esterified fatty acid composition in obese men (N = 11) at baseline, the middle and end of the study

From: Chronic treatment with krill powder reduces plasma triglyceride and anandamide levels in mildly obese men

Fatty acid Baseline Week 12 Week 24
C12:0 0.10 ± 0.05 0.12 ± 0.07 0.12 ± 0.11
C14:0 1.25 ± 0.41 1.18 ± 0.41 1.19 ± 0.56
C15:0 0.20 ± 0.04 0.19 ± 0.04 0.20 ± 0.05
C16:0 23.27 ± 2.53 22.28 ± 2.41 22.78 ± 3.10
C16:1 2.49 ± 0.52 2.03 ± 0.59 ** 2.19 ± 0.82
C18:0 6.56 ± 0.37 6.45 ± 0.46 6.42 ± 0.41
C18:1,t6-11 0.35 ± 0.13 0.47 ± 0.32 0.35 ± 0.14
C18:1,c9 23.10 ± 2.54 22.06 ± 2.05 21.54 ± 2.21 **
C18:1,c11 1.56 ± 0.29 1.52 ± 0.21 1.56 ± 0.25
C18:2,n-6 23.11 ± 3.78 25.25 ± 4.06 ** 24.37 ± 4.99
C20:0 0.25 ± 0.05 0.25 ± 0.04 0.25 ± 0.05
C18:3,n-6 0.45 ± 0.18 0.37 ± 0.09 0.35 ± 0.09
C18:3,n-3 0.73 ± 0.30 0.75 ± 0.26 0.73 ± 0.19
C20:1,n-9 0.15 ± 0.05 0.15 ± 0.04 0.16 ± 0.04
C20:2,n-6 0.19 ± 0.04 0.18 ± 0.03 0.17 ± 0.04
C22:0 0.56 ± 0.13 0.60 ± 0.14 0.60 ± 0.16
C20:3,n-6 1.51 ± 0.21 1.33 ± 0.17 * 1.38 ± 0.15 *
C20:4,n-6 (AA) 4.85 ± 1.15 5.00 ± 0.78 5.30 ± 1.13
C20:4,n-3 0.10 ± 0.04 0.10 ± 0.03 0.09 ± 0.03
C20:5,n-3 (EPA) 0.75 ± 0.24 1.24 ± 0.20 *** 1.15 ± 0.43 ***
C24:0 0.54 ± 0.15 0.54 ± 0.16 0.54 ± 0.16
C24:1 1.00 ± 0.30 1.02 ± 0.19 1.04 ± 0.29
C22:5,n-3 0.47 ± 0.08 0.53 ± 0.08 * 0.52 ± 0.08 *
C22:6,n-3 (DHA) 1.37 ± 0.32 1.67 ± 0.37 * 1.72 ± 0.28 ***
  1. Data are expressed as mean g/100g FAME in plasma ± S.D. P-value was calculated at week 12 and 24 vs. baseline using a paired T-test. *, P < 0.05; **, P < 0.01; ***, P < 0.005 vs baseline.